Q-omics provides the consensus-scored BCYRN1 profile across patient tissues and cancer cell-line models. BCYRN1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, BCYRN1 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, BCYRN1 RNA expression shows 16,441 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, COAD, and GBM as cancer lineages where BCYRN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCYRN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCYRN1 survival associations across molecular data types. BCYRN1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCYRN1 RNA expression–survival associations across cancer types. High BCYRN1 expression shows unfavorable associations in LIHC, UCEC, SKCM and MESO, but favorable associations in LGG and BLCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for BCYRN1 RNA expression.
This table summarizes BCYRN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for BCYRN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCYRN1 shows lower tumor expression in KIRC and higher tumor expression in COAD, CHOL, LUAD, LIHC and READ. The COAD box plot shows higher BCYRN1 RNA expression in tumor versus normal tissue (log2 FC = +0.398, t-test p < 0.001).
This table shows molecular features associated with BCYRN1 in patient tissues and cancer cell lines. In patient samples, BCYRN1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
